Liquid biopsies are a non-invasive alternative to traditional biopsies, analyzing circulating tumor DNA (ctDNA) in a patient's blood. While they are not yet a complete replacement, liquid biopsies offer significant advantages, such as easier sample collection and the ability to monitor disease progression and treatment response in real-time. They are particularly useful for detecting minimal residual disease and for patients where traditional biopsy methods are challenging.
